Table 1.
Characteristics at Baseline Between PDT Group and Placebo Group
| Characteristics | PDT Group | Placebo Group | p value |
|---|---|---|---|
| Age, yr | 24.86±0.47 | 25.58±0.50 | 0.292 |
| Height, cm | 162.73±0.67 | 161.31±0.69 | 0.141 |
| Weight, kg | 53.15±0.86 | 53.54±1.42 | 0.816 |
| BMI, kg/m2 | 20.05±0.28 | 20.49±0.46 | 0.415 |
| Gravidity | 0.11±0.05 | 0.29±0.10 | 0.113 |
| Parity | 0.01±0.02 | 0.09±0.04 | 0.166 |
| Age at menarche, yr | 12.93±0.14 | 13.06±0.16 | 0.539 |
| Menstrual cycle, days | 29.47±0.42 | 29.65±0.34 | 0.742 |
| VAS scores | |||
| All patients | 5.19±0.28 | 5.35±0.32 | 0.813 |
| PGF2α, pg/mL | 44.61±1.16 | 45.28±1.50 | 0.770 |
| PGE2, pg/mL | 588.13±167.46 | 579.22±159.30 | 0.991 |
Note: Data are presented as mean ± SEM or number (percentage).
Abbreviations: PDT, BMI, body mass index; VAS, visual analog scale; PGF2α, prostaglandin F2 alpha; PGE2, prostaglandin E2.